Magnet Biomedicine wants to give difficult proteins a useful introduction

Some proteins resist a drug’s advances. Magnet Biomedicine is recruiting a second protein to help - a molecular matchmaking strategy that has attracted $50 million in venture funding and an oncology agreement with Lilly.